Revance Therapeutics (RVNC) Tops Q3 EPS by 6c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/18/2026
- Nasdaq futures lead Wall St gains as oil retreat eases inflation worries
- Oil prices set for weekly fall on easing fears over Saudi supply disruption
- The Fed is hiking. Why isn't UBS worried about stocks?
- Wall Street on Fed rate hike: 'As hawkish as it gets'
- RBC bullish on Kraft Heinz, sees return to growth in 2027
Revance Therapeutic (RVNC) PT Lowered to $42 at Mizuho Securities
November 2, 2018 7:25 AM EDTMizuho Securities analyst, Difei Yang, lowered the price target on Revance Therapeutic (NASDAQ: RVNC) to $42.00 (from $48.00) while maintaining a Buy rating following the company's 3Q earnings report. Revance reported 3Q EPS of $(0.91) that is slightly above FactSet consensus of $(0.92). $2.4 mil of revenue was... More
